{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T17:09:29Z","timestamp":1788196169311,"version":"build-2803163510"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.semarthrit.2023.152358","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T21:11:39Z","timestamp":1704834699000},"page":"152358","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Moving urate-lowering therapy in gout beyond guideline recommendations"],"prefix":"10.1016","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0138-2912","authenticated-orcid":false,"given":"Lisa K","family":"Stamp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Dalbeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.semarthrit.2023.152358_bib0001","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/acr.24180","article-title":"2020 American college of rheumatology guideline for the management of gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152358_bib0002","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.semarthrit.2023.152358_bib0003","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/rheumatology\/kex156","article-title":"The British society for rheumatology guideline for the management of gout","volume":"56","author":"Hui","year":"2017","journal-title":"Rheumatology."},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152358_bib0004","doi-asserted-by":"crossref","first-page":"58","DOI":"10.7326\/M16-0570","article-title":"Management of acute and recurrent gout: a clinical practice guideline from the American college of physicians","volume":"166","author":"Qaseem","year":"2017","journal-title":"Ann Int Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152358_bib0005","doi-asserted-by":"crossref","first-page":"71","DOI":"10.7326\/M16-2401","article-title":"To treat or not to treat (to target) in gout","volume":"166","author":"Neogi","year":"2017","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.semarthrit.2023.152358_bib0006","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrrheum.2017.126","article-title":"Discordant American college of physicians and international rheumatology guidelines for gout management: consensus statement of the gout, hyperuricemia and crystal-associated disease network (G-CAN)","volume":"13","author":"Dalbeth","year":"2017","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152358_bib0007","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40271-016-0184-x","article-title":"What outcomes are important for gout patients? in-depth qualitative research into the gout patient experience to determine optimal endpoints for evaluating therapeutic interventions","volume":"10","author":"Tatlock","year":"2017","journal-title":"Patient - Patient-Centered Outcomes Res"},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152358_bib0008","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3899\/jrheum.131258","article-title":"Research priorities in gout: the patient perspective","volume":"41","author":"Singh","year":"2014","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2023.152358_bib0009","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.semarthrit.2020.06.001","article-title":"The experience of a gout flare: a meta-synthesis of qualitative studies","volume":"50","author":"Stewart","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.semarthrit.2023.152358_bib0010","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/art.1780150209","article-title":"The influence of temperature on the solubility of monosodium urate","volume":"15","author":"Loeb","year":"1972","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.semarthrit.2023.152358_bib0011","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1136\/annrheumdis-2014-205304","article-title":"Hyperuricaemia and gout \u2013 time for a new staging system?","volume":"73","author":"Dalbeth","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.semarthrit.2023.152358_bib0012","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1002\/art.40572","article-title":"Brief report: monosodium urate monohydrate crystal deposits are common in asymptomatic sons of patients with gout: the sons of gout study","volume":"70","author":"Abhishek","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152358_bib0013","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0002-9343(87)90441-4","article-title":"Asymptomatic hyperuricaemia: risks and consequence in the normative aging study","volume":"82","author":"Campion","year":"1987","journal-title":"Am J Med"},{"issue":"7","key":"10.1016\/j.semarthrit.2023.152358_bib0014","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1136\/annrheumdis-2017-212288","article-title":"Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis","volume":"77","author":"Dalbeth","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.semarthrit.2023.152358_bib0015","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1002\/acr.22855","article-title":"Association of serum uric acid and disease duration with frequent gout attacks: a case\u2013control study","volume":"68","author":"Abhishek","year":"2016","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152358_bib0016","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/03007995.2016.1239193","article-title":"Serum uric acid levels and the risk of flares among gout patients in a US managed care setting","volume":"33","author":"Shiozawa","year":"2017","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152358_bib0017","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3899\/jrheum.160452","article-title":"Serum Uric acid and the risk of incident and recurrent gout: a systematic review","volume":"44","author":"Shiozawa","year":"2017","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2023.152358_bib0018","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/art.42055","article-title":"Intensive serum urate lowering with oral urate-lowering therapy for erosive gout: a randomized double-blind controlled trial","volume":"74","author":"Dalbeth","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2023.152358_bib0019","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00296-009-1002-8","article-title":"Ultrasonography shows disappearance of monosodium urate crystal deposition on the hyaline cartilage after sustained normouricaemia is achieved","volume":"30","author":"Thiele","year":"2010","journal-title":"Rheumatol Int"},{"issue":"5","key":"10.1016\/j.semarthrit.2023.152358_bib0020","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1136\/ard-2022-223597","article-title":"Tsai-Fan Yu: physician and researcher who established modern gout management","volume":"82","author":"Dalbeth","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152358_bib0021","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1136\/ard.2006.060368","article-title":"Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout","volume":"66","author":"Pascual","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152358_bib0022","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1136\/annrheumdis-2016-210872","article-title":"A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout","volume":"76","author":"Stamp","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.semarthrit.2023.152358_bib0023","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1136\/annrheumdis-2017-211873","article-title":"Allopurinol dose escalation to achieve serum urate below 6mg\/dL: an open-label extension study","volume":"76","author":"Stamp","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"10156","key":"10.1016\/j.semarthrit.2023.152358_bib0024","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(18)32158-5","article-title":"Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial","volume":"392","author":"Doherty","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2023.152358_bib0025","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1016\/S2665-9913(21)00319-2","article-title":"Association between serum urate and flares in people with gout and evidence for surrogate status: a secondary analysis of two randomised controlled trials","volume":"4","author":"Stamp","year":"2022","journal-title":"Lancet Rheumatol"},{"issue":"15","key":"10.1016\/j.semarthrit.2023.152358_bib0026","doi-asserted-by":"crossref","first-page":"R137","DOI":"10.1186\/ar4318","article-title":"Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy","volume":"15","author":"Baraf","year":"2013","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152358_bib0027","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/acr.22059","article-title":"Exploratory study of radiographic change in patients with tophaceous gout treated with intensive urate-lowering therapy","volume":"66","author":"Dalbeth","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2023.152358_bib0028","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keac173","article-title":"Dual-energy CT assessment of rapid monosodium urate depletion and bone erosion remodelling during pegloticase plus methotrexate co-therapy","author":"Dalbeth","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.semarthrit.2023.152358_bib0029","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/art.40929","article-title":"Effects of allopurinol dose escalation on bone erosion and urate volume in gout: a dual-energy computed tomography imaging study within a randomized, controlled trial","volume":"71","author":"Dalbeth","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.semarthrit.2023.152358_bib0030","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0022-0248(81)90068-3","article-title":"The crystallization and dissolution of sodium urate","volume":"53","author":"Lam-Erwin","year":"1981","journal-title":"J Cryst Growth"},{"issue":"4","key":"10.1016\/j.semarthrit.2023.152358_bib0031","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.10511","article-title":"Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthritis Care Res"},{"issue":"10","key":"10.1016\/j.semarthrit.2023.152358_bib0032","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American college of rheumatology guidelines for the management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricaemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res"},{"issue":"5","key":"10.1016\/j.semarthrit.2023.152358_bib0033","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/acr2.11243","article-title":"Designing a strategy trial for the management of gout: the use of a modified delphi panel","volume":"3","author":"Solomon","year":"2021","journal-title":"ACR Open Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152358_bib0034","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s11606-017-4233-5","article-title":"Effects of discontinuation of urate-lowering therapy: a systematic review","volume":"33","author":"Beslon","year":"2018","journal-title":"J Gen Intern Med"},{"issue":"5","key":"10.1016\/j.semarthrit.2023.152358_bib0035","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.semarthrit.2017.09.007","article-title":"Medication adherence among patients with gout: a systematic review and meta-analysis","volume":"47","author":"Scheepers","year":"2018","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.semarthrit.2023.152358_bib0036","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1002\/art.30649","article-title":"A two-stage approach to the treatment of hyperuricemia in gout: the \"dirty dish\" hypothesis","volume":"63","author":"Perez-Ruiz","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152358_bib0037","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s13063-023-07242-y","article-title":"Urate-lowering therapy following a treat-to-target continuation strategy compared to a treat-to-avoid-symptoms discontinuation strategy in gout patients in remission (GO TEST Finale): study protocol of a multicentre pragmatic randomized superiority trial","volume":"24","author":"Peeters","year":"2023","journal-title":"Trials"},{"issue":"2","key":"10.1016\/j.semarthrit.2023.152358_bib0038","doi-asserted-by":"crossref","first-page":"229","DOI":"10.7326\/0003-4819-64-2-229","article-title":"Allopurinol in the treatment of gout","volume":"64","author":"Rundles","year":"1966","journal-title":"Ann Int Med"},{"key":"10.1016\/j.semarthrit.2023.152358_bib0039","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricaemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.semarthrit.2023.152358_bib0040","first-page":"1888","article-title":"Ultrasonographic measurement of tophi as an outcome measure for chronic gout","volume":"34","author":"Perez-Ruiz","year":"2007","journal-title":"J Rheumatol"},{"issue":"10","key":"10.1016\/j.semarthrit.2023.152358_bib0041","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1136\/ard.2008.099713","article-title":"Dual energy computed tomography in tophaceous gout","volume":"68","author":"Choi","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152358_bib0042","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13075-018-1714-9","article-title":"Monosodium urate burden assessed with dual-energy computed tomography predicts the risk of flares in gout: a 12-month observational study : MSU burden and risk of gout flare","volume":"20","author":"Pascart","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.semarthrit.2023.152358_bib0043","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1136\/annrheumdis-2013-205036","article-title":"Zoledronate for prevention of bone erosion in tophaceous gout: a randomised, double-blind, placebo-controlled trial","volume":"73","author":"Dalbeth","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"45","key":"10.1016\/j.semarthrit.2023.152358_bib0044","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.semarthrit.2015.05.005","article-title":"An open-label, 6-month study of allopurinol safety in gout: the LASSO study","volume":"2015","author":"Becker","year":"2015","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152358_bib0045","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/cts.12686","article-title":"Relationships between allopurinol dose, oxypurinol concentration and urate-lowering response-in search of a minimum effective oxypurinol concentration","volume":"13","author":"Stamp","year":"2020","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.semarthrit.2023.152358_bib0046","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/0002-9343(64)90131-7","article-title":"Effect of allopurinol (4-Hydroxypyrazolo-(3,4-D)pyrimadine) on serum and urinary uric acid in primary and secondary gout","volume":"37","author":"Yue","year":"1964","journal-title":"Am J Med"},{"issue":"6","key":"10.1016\/j.semarthrit.2023.152358_bib0047","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/bcp.12126","article-title":"Understanding the dose-response relationship of allopurinol: predicting the optimal dosage","volume":"76","author":"Graham","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.semarthrit.2023.152358_bib0048","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1111\/bcp.13307","article-title":"Individualising the dose of allopurinol in patients with gout","volume":"83","author":"Kannangara","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.semarthrit.2023.152358_bib0049","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/bcp.12799","article-title":"Predicting response to allopurinol in patients with gout","volume":"81","author":"Wright","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.semarthrit.2023.152358_bib0050","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s00228-013-1478-8","article-title":"A population pharmacokinetic model for allopurinol and oxypurinol in patients with gout","volume":"69","author":"Wright","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.semarthrit.2023.152358_bib0051","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/s13075-017-1491-x","article-title":"The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized clinical trial","volume":"19","author":"Stamp","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"10.1016\/j.semarthrit.2023.152358_bib0052","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/rheumatology\/kes091","article-title":"Furosemide increases plasma oxypurinol without lowering serum urate \u2013 a complex drug interaction: implications for clinical practice","volume":"51","author":"Stamp","year":"2012","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.semarthrit.2023.152358_bib0053","doi-asserted-by":"crossref","first-page":"904","DOI":"10.3899\/jrheum.101160","article-title":"Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout","volume":"38","author":"Stocker","year":"2011","journal-title":"J Rheumatol"},{"issue":"18","key":"10.1016\/j.semarthrit.2023.152358_bib0054","article-title":"ABCG2 rs2231142 (Q141K) and oxypurinol concentrations in people with gout receiving allopurinol","volume":"S1347-4367","author":"Stamp","year":"2018","journal-title":"Drug Metab Pharmacokinet"},{"issue":"5","key":"10.1016\/j.semarthrit.2023.152358_bib0055","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/cpt.89","article-title":"Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response","volume":"97","author":"Wen","year":"2015","journal-title":"Clin Pharm Ther"},{"issue":"2","key":"10.1016\/j.semarthrit.2023.152358_bib0056","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/tpj.2015.101","article-title":"ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout","volume":"17","author":"Roberts","year":"2017","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.semarthrit.2023.152358_bib0057","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.dmpk.2017.11.002","article-title":"Investigation of the transport of xanthine dehydrogenase inhibitors by the urate transporter ABCG2","volume":"33","author":"Nakamura","year":"2018","journal-title":"Drug Metabol Pharmacokinet"},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152358_bib0058","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/cpt.1439","article-title":"Genome-wide association and functional studies reveal novel pharmacological mechanisms for allopurinol","volume":"106","author":"Brackman","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.semarthrit.2023.152358_bib0059","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/cts.12992","article-title":"Oxypurinol pharmacokinetics and pharmacodynamics in healthy volunteers: influence of BCRP Q141K polymorphism and patient characteristics","volume":"14","author":"Vora","year":"2021","journal-title":"Clin Transl Sci"},{"issue":"12","key":"10.1016\/j.semarthrit.2023.152358_bib0060","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/acr2.11199","article-title":"Patient perspectives on gout and gout treatments: a patient panel discussion that informed the 2020 American college of rheumatology treatment guideline","volume":"2","author":"Singh","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152358_bib0061","article-title":"Predictors of patient and physician assessments of gout control","author":"Dalbeth","year":"2022","journal-title":"Arthritis Care Res"},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152358_bib0062","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jbspin.2018.10.008","article-title":"Implication of nurse intervention on engagement with urate-lowering drugs: a qualitative study of participants in a RCT of nurse led care","volume":"86","author":"Latif","year":"2019","journal-title":"Joint Bone Spine"},{"issue":"8","key":"10.1016\/j.semarthrit.2023.152358_bib0063","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/acr.21955","article-title":"Do patient preferences for core outcome domains for chronic gout studies support the validity of composite response criteria?","volume":"65","author":"Taylor","year":"2013","journal-title":"Arthritis Care Res"},{"issue":"9","key":"10.1016\/j.semarthrit.2023.152358_bib0064","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1093\/rheumatology\/key155","article-title":"Medication adherence among gout patients initiated allopurinol: a retrospective cohort study in the clinical practice research datalink (CPRD)","volume":"57","author":"Scheepers","year":"2018","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.semarthrit.2023.152358_bib0065","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3899\/jrheum.170199","article-title":"The Cost-effectiveness of biannual serum urate (SU) monitoring after reaching target in gout: a health economic analysis comparing SU monitoring","volume":"45","author":"Robinson","year":"2018","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152358_bib0066","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/clpt.2011.113","article-title":"Relationship between serum urate and plasma oxypurinol \u2013 Is there a target plasma oxypurinol to achieve serum urate <6\u00a0mg\/dL?","volume":"90","author":"Stamp","year":"2009","journal-title":"Clin Pharm Ther"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017223002007?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017223002007?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:12:21Z","timestamp":1758733941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017223002007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":66,"alternative-id":["S0049017223002007"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152358","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Moving urate-lowering therapy in gout beyond guideline recommendations","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152358","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152358"}}